Barclays Starts CRISPR Therapeutics (CRSP) at Overweight

November 14, 2016 7:55 AM EST
Get Alerts CRSP Hot Sheet
Price: $19.03 --0%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade CRSP Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Barclays initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with an Overweight rating and a price target of $22.00.

For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.

Shares of CRISPR Therapeutics closed at $17.50 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

New Coverage

Related Entities

Barclays

Add Your Comment